文献速递白血病造血干细胞移植与细胞治疗

PLAT-02与PLAT-03研究结果:评估CD19 CAR-T细胞疗法及表达CD19的T-APC支持在儿童B细胞急性淋巴细胞白血病中的效果

Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL.
PubMed 文献 · Blood · 2025-01-01

PLAT-02是一项2期试验,评估SCRI-CAR19在儿童及年轻成人B细胞急性淋巴细胞白血病中的疗效,可评估疗效队列72例患者中微小残留病阴性完全缓解率为89%,1年和2年无白血病生存率分别为0.71和0.64。 companion pilot PLAT-03入组26例患者,19例接受表达截短CD19的T细胞抗原呈递细胞(T-APC)输注,未观察到细胞因子释放综合征或神经毒性,T-APC输注改善了CAR-T细胞持续性(P = .03)。

要点

  • PLAT-02中可评估疗效的72例患者微小残留病阴性完全缓解率为89%。
  • 低疾病负荷患者1年无白血病生存率显著更高(0.91 vs 0.42)。
  • PLAT-03中T-APC输注后未观察到细胞因子释放综合征或神经毒性。

核心结论

  • PLAT-02中SCRI-CAR19在儿童及年轻成人B细胞急性淋巴细胞白血病中取得89%的微小残留病阴性完全缓解率,1年和2年无白血病生存率分别为0.71和0.64。
  • PLAT-03中T-APC输注改善了CAR-T细胞持续性(P = .03),基于这些初步结果需进一步探索系列人工CD19抗原暴露。

研究设计与样本

  • PLAT-02为2期试验,评估SCRI-CAR19(含FMC63单链可变片段和4-1BB共刺激的第二代CAR-T细胞产品)在儿童及年轻成人B细胞急性淋巴细胞白血病患者中的效果;可评估疗效队列72例,中位年龄12.5岁,接受氟达拉滨/环磷酰胺清淋后输注1 × 10^6 CAR+ T细胞/kg。
  • PLAT-03为伴随研究,评估外源性CD19抗原刺激,通过系列输注表达截短CD19的T细胞抗原呈递细胞(T-APC);入组26例患者,19例接受T-APC输注。

主要发现

  • PLAT-02可评估疗效队列(n = 72)的微小残留病阴性完全缓解率为89%。
  • PLAT-02的1年和2年无白血病生存率分别为0.71(95% CI,0.58-0.81)和0.64(95% CI,0.51-0.75)。
  • 低疾病负荷患者1年无白血病生存率显著高于高疾病负荷患者(0.91 vs 0.42)。
  • 输注后CAR-T细胞快速体内收缩者6个月内CAR丢失比例为57%,无快速收缩者为19%。
  • PLAT-03中T-APC输注后未观察到细胞因子释放综合征或神经毒性;T-APC输注改善持续性(P = .03),快速CAR-T细胞收缩者中T-APC组早期CAR丢失比例为20%,无T-APC组为57%。

关键数值与推荐

  • PLAT-02中3/4级不良事件最常见包括细胞因子释放综合征(13%)和神经毒性(16%)。
  • PLAT-03中T-APC输注后未观察到细胞因子释放综合征或神经毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出基于这些初步结果需进一步探索系列人工CD19抗原暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study reports outcomes of Pediatric Leukemia Adoptive Therapy 02 (PLAT-02), a phase 2 trial of SCRI-CAR19, a second-generation chimeric antigen receptor (CAR) T-cell product with FMC63 single-chain variable fragment and 4-1BB costimulation, in pediatric and young adult patients with B-cell acute lymphoblastic leukemia; and PLAT-03, a companion study evaluating exogenous CD19 antigen stimulation with serial infusions of T cells expressing truncated CD19, T-cell antigen-presenting cells (T-APCs). The efficacy cohort of PLAT-02 (n = 72 patients; median age 12.5 years) received fludarabine/cyclophosphamide lymphodepletion followed by a dose of 1 × 106 CAR+ T cells per kg. The minimal residual disease-negative complete remission rate was 89%. Leukemia-free survival (LFS) at 1 and 2 years was 0.71 (95% confidence interval [CI], 0.58-0.81) and 0.64 (95% CI, 0.51-0.75), respectively. Patients with low disease burden had significantly higher 1-year LFS (0.91 vs 0.42). Rapid in vivo contraction of CAR T cells after infusion was associated with CAR loss within 6 months compared to those without rapid contraction (57% vs 19%). Most common grade 3/4 adverse events included cytokine release syndrome in 13% and neurotoxicity in 16%. The companion pilot, PLAT-03, enrolled 26 patients, and 19 received T-APCs. Neither cytokine-release syndrome nor neurotoxicity was observed after T-APC infusion. T-APC infusions in patients improved persistence (P = .03), with rapid CAR T-cell contraction being associated with decreased early CAR loss (20% with T-APC vs 57% without). Further exploration of serial artificial CD19 antigen exposure is warranted based on these pilot results. PLAT-02 and PLAT-03 trials were registered at www.clinicaltrials.gov as #NCT02028455 and #NCT03186118, respectively.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Annesley C, Seidel K, Wu Q, et al. Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL. Blood. 2025. PMID: 40233328. doi:10.1182/blood.2025028359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。